Nivalin (Galantamine Hydrobromide)

Galantamine, the active ingredient in Nivalin, is an acetylcholinesterase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of mild to moderate Alzheimer’s disease in adult patients, aiming to improve cognitive and functional abilities. GNH USA supplies Nivalin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution in multiple jurisdictions.

Galantamine is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cholinergic pathways.

Mild to moderate Alzheimer’s disease: improves cognition, memory and attention, supporting daily functioning. Alzheimer’s‑related cognitive decline: slows the rate of deterioration in learning and recall tasks. Behavioral symptoms of Alzheimer’s disease: may reduce agitation and improve overall patient cooperation.

Galantamine may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Loss of appetite - Dizziness - Fatigue

Serious or Rare Side Effects: - Severe bradycardia or heart block - Hepatotoxicity (elevated liver enzymes)

When prescribing Galantamine, clinicians should consider several safety measures.

Dose initiation: start with a low dose and titrate gradually under medical supervision. Cardiac monitoring: avoid in patients with sick sinus syndrome or conduction abnormalities. Gastrointestinal risk: monitor for persistent nausea or vomiting which may lead to dehydration. Renal impairment: adjust dose in patients with severe renal dysfunction. Concomitant anticholinergic drugs: may reduce therapeutic effect. Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture.

Galantamine can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concurrent use with potent anticholinergic agents: may antagonize galantamine’s effect. - Combination with other acetylcholinesterase inhibitors: risk of excessive cholinergic activity. - Use with beta‑blockers in patients with bradycardia: may exacerbate heart‑rate reduction.

Moderate Interactions (Monitor Closely): - CYP2D6 or CYP3A4 inhibitors (e.g., fluoxetine, ketoconazole): may increase galantamine plasma levels. - CNS depressants (e.g., benzodiazepines): may enhance dizziness or sedation.